Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Low-density lipoprotein receptor class A domain-containing protein 3 (LDLRAD3) is a conserved cell-surface protein that belongs to the LDL receptor family and contains a characteristic LDL receptor type-A module. It is expressed in neurons, epithelial cells, myeloid cells, and muscle. LDLRAD3 acts as a recently identified receptor for Venezuelan equine encephalitis virus (VEEV), mediating viral attachment and entry in host cells. Biochemical studies indicate it is involved in receptor-mediated endocytosis and may regulate amyloid precursor protein (APP) processing, potentially influencing amyloid-beta peptide production, which has roles in neurodegenerative pathology. The protein is further predicted to regulate E3 ubiquitin ligase activity and may modulate protein degradation pathways. The endogenous ligand(s) for LDLRAD3 remain unknown, and no approved drugs are currently known to target this protein directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Low-density lipoprotein receptor class A domain-containing protein 3 (LDLRAD3).